LianBio (LIANY)

Market Cap	31.81M
Revenue (ttm)	n/a
Net Income (ttm)	-87.98M
Shares Out	108.17M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,735
Open	0.291
Previous Close	0.294
Day's Range	0.291 - 0.294
52-Week Range	0.241 - 4.990
Beta	0.00
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 163
• Stock Exchange: OTCMKTS
• Ticker Symbol: LIANY